Emyria Expands Investor Access Into Europe
Released
Released
Announcement PDF
Emyria ASX Announcement | 12 Feb 2026
ASX RELEASE.
12 February 2026
EMYRIA EXPANDS INVESTOR ACCESS INTO EUROPE
Emyria securities to be traded via Frankfurt Quotation Board (Open Market) broadening
investor reach following multi-site clinical expansion and reimbursement foundations.
Emyria Limited (ASX: EMD) (“Emyria”, or the “Company”) a leader in developing and delivering
innovative mental health treatments, has commenced a structured European investor
engagement program to expand international shareholder participation and awareness of the
Company’s integrated, reimbursement-backed mental health clinical model.
Strategic Rationale for European Engagement
Europe represents one of the most active global regions for healthcare innovation,
institutional capital allocation and reimbursement-driven service models, particularly within
mental health and neuroscience. Across the region, institutional and specialist investors are
increasingly focused on scalable, evidence-based treatment platforms supported by clinical
validation, regulatory engagement and established healthcare infrastructure.
A Frankfurt Open Market presence is anticipated to improve European institutional access by
providing local market visibility and participation pathways, facilitate valuation benchmarking
against global mental health peers, and support long-term liquidity alongside the Company’s
ASX listing.
Notably, being on the Frankfurt Open Market does not impose any additional compliance or
regulatory requirements for the company, nor does it have any ongoing administrative costs.
• European investor engagement program launched to broaden international
shareholder participation and increase visibility across key European capital markets.
• EMD securities can be traded in Europe on the Frankfurt Open Market - ticker
(FSE:Q84).
• Frankfurt stock exchange is second largest in Europe and provides European
institutional and specialist investors with local market access, enhanced visibility, and an
additional participation pathway alongside the Company’s ASX listing.
• Initiative aligns with growing European institutional focus on innovative mental
health services that are evidence-based and reimbursed, including next-generation
therapies for conditions such as depression and PTSD.
• Specialist European IR advisor appointed - Dr Reuter Investor Relations engaged to
support European investor engagement, with a focus on the DACH region (Germany,
Austria and Switzerland).
• European engagement follows a period of accelerating operational growth
supported by delivering long-term durable clinical outcomes, strong quarterly revenue
growth, a multi-state Empax clinic footprint and dual reimbursement pathways with
both private insurers and government payers.
ASX RELEASE.
Emyria ASX Announcement | 12 Feb 2026 2
Executive Chairman of Emyria, Greg Hutchinson, said:
"Emyria has reached a stage in its development where our national clinic footprint,
accelerating revenue growth, dual reimbursement pathways and durable real-world PTSD
outcomes position us for broader international engagement.
Commencing structured European investor outreach is a logical extension of our strategy to
improve accessibility for institutional and specialist healthcare investors, while our
operational focus remains firmly on what has brought us to this point. That is, clinical
execution, durable patient outcomes, disciplined expansion and the continued broadening
of reimbursement pathways."
European Investor Relations Support
To support its European engagement activities, Emyria has engaged Dr Reuter Investor
Relations, a specialist European investor relations firm with extensive experience assisting
ASX-listed life-sciences and healthcare companies in building long-term investor awareness
and participation across European capital markets, particularly within the DACH region.
Dr Eva Reuter, CEO of Dr Reuter Investor Relations, commented:
“Emyria joining the Frankfurt Open Market comes at a time of accelerating European institutional
and specialist interest in next-generation mental health therapies. Across Europe, investor
attention is increasingly aligned with clinical momentum in areas such as psychedelic-assisted
approaches for depression and PTSD—supported by active clinical programs in the region,
including the European arm of COMPASS Pathways’ Phase 3 psilocybin program in treatment-
resistant depression and European MDMA-assisted psychotherapy studies. It also places Emyria
alongside sector peers that already trade on the Frankfurt Open Market.”
This release has been approved by the Board of Emyria.
Greg Hutchinson | Executive Chair
1300 436 363 | investors@emyria.com
ASX RELEASE.
Emyria ASX Announcement | 12 Feb 2026 3
CAUTIONARY NOTE ON FORWARD-LOOKING STATEMENTS Any statements in this press release about
future expectations, plans and prospects for the Company, the Company’s strategy, future operations, and
other statements containing the words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,”
“predict,” “project,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” and similar expressions,
constitute forward-looking statements. Actual results may differ materially from those indicated by such
forward-looking statements as a result of various important factors, including: the Company’s ability to
successfully develop its product candidates and timely complete its planned clinical programs and the
Company’s ability to obtain marketing approvals for its product candidates. In addition, the forward-looking
statements included in this press release represents the Company’s views as of the date hereof. The Company
anticipates that subsequent events and developments will cause the Company’s views to change. However,
while the Company may elect to update these forward-looking statements at some point in the future, the
Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied
upon as representing the Company’s views as of any date subsequent to the date hereof.
Risks associated with the use of MDMA, MDMA-inspired compounds and psilocybin
All medicines carry risks and specialist prescribers, such as registered psychiatrists, are best placed to assess
the suitability of a new medication against a patient’s individual circumstances and medical history before
proceeding. Adverse effects of MDMA include high blood pressure, increased pulse rate, faintness, and panic
attacks, and in some rare cases it can cause loss of consciousness or trigger seizures. Other side effects include
involuntary jaw clenching, decreased appetite, restless legs, nausea, headache, sweating and muscle/joint
stiffness. Adverse effects of psilocybin can include temporary increase in blood pressure and a raised heart rate.
There may be some risk of psychosis in predisposed individuals. The effects of MDMA and psilocybin are
unlikely at low doses in the treatment regimens used in psychedelic-assisted psychotherapy while
appropriately managed in a controlled environment with direct medical supervision. The risk profile of the
MDMA inspired compounds is currently unknown.
The availability of these products is subject to the safety and efficacy of the products being tested through
clinical trials. Emyria makes no representations or warranties as to the safety or efficacy of the products or the
products’ ability (or the ability of its key compounds) to be used in the treatment of indications such as PTSD.
There are currently no approved products containing MDMA, psilocybin or MDMA inspired compounds that
the TGA has evaluated for quality, safety and efficacy.
Emyria Limited develops and delivers new treatments for mental health and select neurological
conditions through an integrated model of direct clinical services and treatment development:
Emyria Healthcare: Evidence-based treatment for patients not finding relief
from conventional care while also helping evaluate emerging new therapies like
assisted therapy for PTSD and assisted therapy for treatment-resistant depression.
Emyria Data: Robust and ethically sourced Real-World Data gathered with patients
to improve Emyria’s unique therapy and drug development programs.
Emyria’s Pipeline: New psychedelic-assisted therapies and drug treatments for mental
health and select neurological diseases.
EMYRIA’S INTERACTIVE INVESTOR HUB
Investorhub.emyria.com Interact with Emyria’s announcements and
updates by asking questions and comments, which our team can respond
to where possible.
generates
informs
Share your feedback
Discover